Dasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase inhibitors. Dasatinib, a tyrosine kinase inhibitor...
Saved in:
| Main Authors: | Ryan Sabour, Sohrab Kharabaf, Eric Frazier, Matthew Nguyen, Dao Le, Jonathan Zuckerman, Ramy Hanna |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X251322621 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of dasatinib in chronic myeloid leukemia therapy
by: O. Yu. Vinogradova, et al.
Published: (2008-12-01) -
Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia
by: Cheng F, et al.
Published: (2025-05-01) -
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01) -
Successful Pregnancy and Delivery in a Patient with Chronic
Myeloid Leukemia while on Dasatinib Therapy
by: Monika Conchon, et al.
Published: (2010-01-01) -
Neutrophilic eccrine hidradenitis following dasatinib initiation in a patient with chronic myeloid leukemia
by: Avery Watson, M4, et al.
Published: (2025-07-01)